Faculty & Staff

Bio

Dr. Andrews (she/her/hers) is an Assistant Professor of Pediatrics in the Division of Pediatric Infectious Diseases and Immunology at the University of Minnesota who cares for patients both at University of Minnesota Masonic Children's Hospital and Gillette Children's Specialty Healthcare. Dr. Andrews specializes in caring for children with complex infections, immune systems, and/or hardware involvement. Her research focuses on optimizing antimicrobial use, particularly in patient with immunocompromise, and educating future medical providers in the best use of antimicrobials.

Administrator Information

Sandra Streff
Administrative Phone: 612-626-5637

Bio

Craig J. Bierle, PhD, is an Assistant Professor in the Division of Pediatric Infectious Diseases and Immunology. Dr. Bierle received his doctorate in Molecular and Cellular Biology from the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle. He heads a research laboratory that studies viral infections of pregnancy, which are the leading preventable cause of neurologic disabilities in children.

Research Summary

Infection is a leading cause of pregnancy loss, premature birth, and intellectual disability. Certain viruses, including cytomegalovirus (CMV) and Zika virus, can be transmitted across the placenta, infect the fetus, and disrupt normal development. Ethical and technical barriers to studying disease during human pregnancy have limited progress towards an understanding of the molecular mechanisms that underlie in utero infection.

Research in the Bierle lab utilizes guinea pig CMV as a model for congenital CMV disease in humans. Similarities in placentation and gestation between guinea pigs and humans make the rodent a valuable experimental model for the study of infections during pregnancy. The group aims to use emerging technologies including CRISPR/Cas9 genome editing and next generation sequencing to study viral infection at the maternal-fetal interface and identify targets for vaccines or therapeutics that could prevent or mitigate damage from congenital CMV disease.

External Research Support:

Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (R21HD087496

Bio

Dr. Patricia Ferrieri's laboratory is focused on the pathogenesis of infections with group B streptococci (GBS) and host immunity to streptococcal antigens. These investigations have included the epidemiology of maternal and neonatal colonization and infection with GBS, animal models of neonatal sepsis and meningitis, isolation and biochemical and immunological characterization of key antigens of group B streptococci, and human and animal immune responses to these antigens, including the role of monoclonal and polyclonal antibodies in protection against infection. Her laboratory has cloned the gene for a key surface localized protein (glutamine synthetase) of GBS into E. coli , and has used polymerase chain reaction (PCR) technology and nucleotide sequencing and amino acid sequencing of this GBS protein to enhance the research.

Research Summary

In recent years, Ferrieri has focused her research principally on group B Streptococcus, antigens involved in immunity, and vaccine development aimed at prevention of group B Streptococcus infection in newborns. Group B strep, which babies can acquire as they pass through the maternal birth canal, puts them at risk for sepsis and meningitis and can be fatal. Ferrieri's research group collaborated in a five-year, NIH funded study with colleagues at the University of Pittsburgh and Baylor College of Medicine that involved giving experimental group B strep vaccine to non-pregnant women. Her laboratory was responsible for molecular characterization of the group B strep strains of study subjects in advance of their receiving the vaccine and then at specific intervals during the course of the study. Results from the study suggest that the vaccine prevented study subjects from acquiring the type of group B strep that was present in the vaccine. Non-pregnant women who received placebo were less protected. Ferrieri and her colleagues are now correlating the results from antibody analysis with the results of from the molecular analysis of the different group B strep strains. One of the questions the study can help answer is whether bacterial colonization or vaccine-produced antibodies is the primary endpoint for optimal protection. The study could have a major impact for maternal and infant public health globally as well as for the elderly, diabetics, and other populations at risk for group B strep infection. Since the 1990s pregnant women in the U.S. have been tested for group B strep, typically at 35-37 weeks of gestation. Ferrieri introduced a molecular PCR-based assay in the Clinical Microbiology Laboratory, which is now used to test pregnant women in the later stages of pregnancy. The test is more sensitive that the standard group B strep culture for detecting infection.Ferrieri's laboratory is also studying Streptococcus pneumoniae (pneumococcus) and its role in causing otitis media, an infection of the middle ear that can lead to hearing loss in affected children. In an NIH-R01 funded collaboration with colleagues at the U of MN and the University of Alabama in Birmingham, Ferrieri has been investigating protective protein antigens from pneumococcus in otitis media found in the chinchilla, whose ear anatomy mimics closely that of the human ear. The research is designed to contribute to the goal of developing a vaccine that would prevent middle-ear and other pneumococcal infections in young children. Ferrieri and her collaborators are working to extend their findings at the molecular level to shed light on the individual protein-antigen components that could serve as the basis for a universally protective vaccine. Current vaccines can prevent otitis media and other pneumococcus-cased conditions in only about one-fourth of children who receive them. Ferrieri has a career-long view that protein antigens are critical for establishing immunity against various encapsulated bacteria – bacteria that have a polysaccharide coating. Vaccine designs that conjugate polysaccharide antigens with protein antigens may elicit a superior immune response, chiefly through memory B cells.In a controlled trial involving an investigational pneumococcal vaccine and placebo, investigators including Ferrieri (the PI) looked at the immune response in pregnant women both before and after they had given birth, as well as the immune response in their newborns. The newborns from mothers who had received the vaccine while pregnant actually had lower antibody levels than babies born to the mothers who had received placebo, which raises the issue of fetal immune tolerance during pregnancy.In the Clinical Microbiology Laboratory, Ferrieri's team is developing, validating and introducing cutting-edge molecular diagnostic assays to permit rapid detection of pathogens for both in-patients and out-patients of all age groups, leading to improved treatment. New molecular platforms Ferrieri has introduced into the laboratory, in addition to the group B strep PCR assay, performed late in pregnancy, include MALDI-TOF mass spectrometry, which allows rapid identification of bacteria of various complexity as well as yeast and fungi, with a major impact on patient care. Another highly sophisticated test with an impact on patient care and hospital length-of-stays is a nucleic acid microarray assay. The test can be used directly on positive blood cultures of both gram-positive and gram-negative bacteria, with 95-100 percent sensitivity and specificity and with results available in a few hours.

Publications

• Shabayek S, Ferrieri P, Spellerberg B. Group B streptococcal colonization in African countries: Prevalence, capsular serotypes, and molecular sequence types. Pathogens. 2021 Dec 10;10(12):1606. doi: 10.3390/pathogens10121606.
• Arries C, Ferrieri P. Mobiluncus curtisii bacteremia: Case study and literature review. Infect Dis Rep. 2022 Jan 14;14(1):82-87. doi: 10.3390/idr14010009.
• Martinez RJ, Pankratz N, Schomaker M, Daniel J, Beckman K, Karger AB, Thyagarajan BT, Ferreri P, Yohe SL, Nelson AC. Prediction of false positive SARS-CoV-2 molecular results in a high-throughput open platform system. J Mol Diagn. 2021 Jun 8:S1525-1578(21)00166-5. doi: 10.1016/j.jmoldx.2021.05.015
• Ferrieri P, Thonen-Kerr E, Nelson K., Arbefeville S. Prospective evaluation of Xpert® Xpress strep A automated PCR assay vs. Solana® group A streptococcal nucleic acid amplification testing vs. conventional throat culture. Curr Microbiol (2021). https://doi.org/10.1007/s00284-021-0254
• Thomas SN, Altawallbeh G, Zaun CP, Pape KA, Peters JM, Titcombe PJ, Dileepan T, Rapp MJ, Bold TD, Schacker TW, Arbefeville S, Ferrieri P, Thyagarajan B, Jenkins MK, Karger AB. Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA. Clin Biochem. 2021 Feb 1:S0009-9120(21)00027-8. doi: 10.1016/j.clinbiochem.2021.01.010.
• Arbefeville S, Ferrieri P. Role of multiplex molecular diagnosis for acute gastroenteritis. Curr Infect Dis Rep, 2020. 22 (9). Doi: https://doi.org/10.1007/s11908-020-0718-1
• Hillier SL, Ferrieri P, Edwards MS, Ewell M, Ferris D, Fine P, Carey V, Meyn L, Hoagland D, Kasper DL, Paoletti LC, Hill H, Baker CJ. A phase II randomized, control trial of group B streptococcus (GBS) type III capsular polysaccharide -tetanus toxoid (GBS III-TT) vaccine to prevent vaginal colonization with GBS III. Clin Infect Dis. 2018 Oct 3. doi: 10.1093/cid/ciy838.

Bio

Dr. Kaplan is a Professor Emeritus in the Divisions of Pediatric Infectious Disease and of Pediatric Cardiology. As Head of the World Health Organization Collaborating Center for Reference and Research on Streptococci, Dr. Kaplan is primarily interested in the study of group A streptococcal infections and their sequelae. This streptococcal reference and research laboratory was established by the late Dr. Lewis W. Wannamaker in the early 1950's and has maintained a productive record of studying the relationship between the human host and the group A streptococcus. This laboratory is one of only five World Health Organization Collaborating Centers for Reference and Research on Streptococci in the world. Currently, the laboratory addresses the epidemiology, microbiology, immunology of group A streptococci, applied research which involves investigations of the clinical and laboratory diagnosis of streptococcal infections, as well studies of the prevention and therapy of group A streptococcal infections and their sequelae.

Since the latter 1980's and continuing to the present, there has been an unexpected and unexplained resurgence of serious group A streptococcal infections and their sequelae in the United States and throughout the world. Dr. Kaplan's laboratory has been working for a more complete understanding and delineation of this resurgence of serious streptococcal infections. This includes definition of specific organisms involved with this resurgence and examination of the dynamic epidemiology of group A streptococcal serotypes associated with uncomplicated infections. This is important in order to document changes in microbial virulence and communicability of responsible serotypes.

Laboratory emphasis has been concentrated on more completely understanding the shifting prevalence of group A streptococcal strains by correlation of classical laboratory techniques for characterizing group A streptococci with newer molecular techniques. The laboratory is an active participant in an international network of reference laboratories in these studies.

Active studies of the epidemiology and spread of group A streptococci include prospective studies comparing the relative influence of the school and the home in the spread of these organisms in the community.

An active program of applied research of optimal diagnosis and therapy of group A streptococcal infections has been conducted in Dr. Kaplan's laboratory for many years. These have been directed to improving clinical management of patients with streptococcal infections. Recent investigations include optimal and cost-effective laboratory techniques to aid clinicians and epidemiologists. The laboratory has actively participated in studies of optimal antibiotic therapy for these infections. As a part of this latter program, there has been continuing surveillance for detecting clinically significant changes in antimicrobial susceptibility of group A streptococci obtained from countries around the world.

As a laboratory with long standing international interests, epidemiological studies have been carried out in collaboration with colleagues in many parts of the world. Currently, active clinical and laboratory collaborations include countries in Europe, Asia, North Africa, and South America.

A program to further delineate possible genetic predisposition to development of rheumatic fever has been carried out in collaboration with the Postgraduate Institute for Medical Education and Research in India.

Possibilities exist for post-graduate training in Dr. Kaplan's laboratory. Recent laboratory studies have been coordinated with trainees' enrollment in the School of Public Health's Masters Degree Program. In addition, specific laboratory projects have been made available to appropriately qualified individuals from other countries to master laboratory techniques for beginning or upgrading laboratory facilities in other countries.

Bio

Administrator Information

Sandra Streff
Administrative Phone: 612-626-5637

Bio

Administrator Information

Sandra Streff
Administrative Phone: 612-626-5637

Bio

Mark R. Schleiss, MD, is a Professor of Pediatrics in the University of Minnesota Medical School. Dr. Schleiss received his MD degree from the Oregon Health and Sciences University, Portland, Oregon. He completed his residency at Doernbecher Children's Hospital, Oregon Health and Sciences University, Portland, Oregon, and his Pediatric Infectious Diseases fellowship at Seattle Children's Hospital/Medical Center, University of Washington, Seattle, Washington. He also completed a fellowship in Molecular Medicine studying cytomegalovirus (CMV) molecular genetics at the Fred Hutchinson Cancer Research Center, Seattle, Washington.

His work in basic, translational and clinical research related to CMV infection is described at cmv.umn.edu

Clinical Summary

Pediatric Infectious Diseases; Vaccines; Vaccine Advocacy; Antimicrobials and Antivirals; Clinical Virology; Maternal-Fetal Infections

Bio

Dr. Sharon was born and raised in Haifa, Israel, spending as much time as possible at the Mediterranean Sea. He obtained his medical degree at Semmelwies University in Budapest, Hungary. After graduating from the Pediatric residency program at Nationwide Children's Hospital/The Ohio State University in Columbus, Ohio, Dr. Sharon moved to Minneapolis to complete a Pediatric Infectious Disease fellowship at the University of Minnesota. Dr. Sharon then joined the University of Minnesota faculty. He is board certified in both General Pediatrics and Pediatric Infectious Diseases. His clinical duties include roles in both infectious Disease and Pediatric Hospital Medicine. As an infectious disease specialist, he sees patients admitted to the hospital with infectious concerns and sees children and adolescents at his Infectious Disease outpatient clinics. As a Pediatric Hospitalist, Dr. Sharon sees children and adolescents who require hospital admission for general Pediatric issues, and he works at both the M Health Fairview Masonic Children's Hospital and Fairview Ridges Hospital. He is also the director for the University of Minnesota Pediatric Hospital Medicine fellowship program.

His clinical interests include invasive bacterial infections in otherwise healthy children, as well as congenital CMV infection. He's also interested in continuing medical education, and is excited to lead the Hospitalist division's fellowship training program. When not in the hospital you may find him traveling with his family (either biking around town or globetrotting with his wife and three young children), or jumping out of airplanes just for fun.

Administrator Information

Cathy Centola
Administrative Phone: 612-625-6678
Administrative Email: kreme002@umn.edu
Administrative Fax Number: 612-626-1144

Clinical Summary

Infectious disease

Bio

Administrator Information

Sandra Streff
Administrative Phone: 612-626-5637

Bio

Dr. Thielen is a physician-scientist trained in adult and pediatric infectious diseases. She joined the faculty in pediatrics in 2020 and is developing a translational research program focused on the molecular epidemiology and viral pathogenesis of human respiratory viral infections including influenza and respiratory syncytial virus. She also has interests in clinical immunology, the role that host genetic variation plays in the response to infectious diseases, and the global burden of respiratory infections.

Administrator Information

Sandra Streff
Administrative Phone: 612-626-5637

Research Summary

Dr. Thielen has clinical and research interests in the pathogenesis of respiratory viruses, including influenza viruses and respiratory syncytial virus. She will be continuing work started during her fellowship with Dr. Ryan Langlois (Microbiology) studying differences in the innate immune response to these viruses in primary human cells. She also has clinical interests in other infections of immunocompromised patients, clinical immunology, and travel medicine.